STAB News and Press, Statera Biopharma Inc. From 04/13/22

Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma PR Newswire Entolimod is currently in clinical development as a potential treatment for acute radiation syndrome with additional pre...

FORT COLLINS, Colo., March 31, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostas...

Live Conference Call and Webcast at 5:30 p.m. ET FORT COLLINS, Colo., March 28, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immu...

FORT COLLINS, Colo., March 24, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostas...

Statera Biopharma (NASDAQ: STAB) , a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, announced the pricing of its underwritten public offering. The offering is comprised of an estimated 10,843,721 units, offered t...

Statera Biopharma (STAB -39.0%) shares are down after the biopharmaceutical company announced pricing of a ~$5.7M stock offering. The offering comprises ~10.84 units, issued at $0.45/unit, and ~1.72M pre-funded units, offered at $0.44/pre-funded unit. Each unit consists of one share of common...

FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, ...

FORT COLLINS, Colo., March 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostas...

Statera Biopharma (NASDAQ:STAB) said it has started public stock offering while the actual size and other terms remain undisclosed. The offering of units will comprise of one common share and one warrant to purchase additional share each, and pre-funded units. EF Hutton, division of Benchmark...

FORT COLLINS, Colo., March 21, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostas...